A Single-arm, Open-label Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To < =65 Years Of Age
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2015
Price : $35 *
At a glance
- Drugs PF 5212366 (Primary)
- Indications Meningococcal meningitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 17 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.